Want to see LXRX full AI Analyst Report?
LXRX Stock Chart & Stats
$2.29
>-$0.01(-0.43%)
At close: 4:00 PM EDT
$2.29
>-$0.01(-0.43%)
Day’s Range― - ―
52-Week Range$1.03 - $2.68
Previous CloseN/A
Volume1.68M
Average Volume (3M)4.03M
Market Cap
$1.02B
Enterprise Value$919.00
Total Cash (Recent Filing)$190.61M
Total Debt (Recent Filing)$59.28M
Price to Earnings (P/E)―
Beta1.76
Next Earnings
Nov 11, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.15
Shares Outstanding444,955,930
10 Day Avg. Volume2,625,675
30 Day Avg. Volume4,028,280
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)3.88
Price to Sales (P/S)8.38
P/FCF Ratio-6.15
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$6.00Price Target Upside162.01% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.16
Revenue Forecast (FY)$37.94M
Bulls Say, Bears Say
Bulls Say
Late-stage SONATA-HCM PipelineOver-enrollment in a large Phase III study can improve statistical power and support a stronger regulatory package, while advancing the lead program toward a potentially meaningful commercial opportunity in hypertrophic cardiomyopathy.
Sotagliflozin Regulatory ExpansionBroader international regulatory activity expands potential market access for sotagliflozin and diversifies commercialization opportunities, reducing reliance on a single geography if additional approvals translate into durable partner-led sales.
Improved Liquidity And Partnership FundingHigher liquidity and milestone receipts provide resources to fund late-stage development and commercialization preparation. The Novo relationship also validates selected pipeline assets and creates potential for additional non-product funding.
Bears Say
Persistent Cash BurnContinued negative cash generation means Lexicon remains dependent on existing liquidity, financing or partner payments to sustain operations. Prolonged development spending without a return to profitability could weaken financial flexibility over time.
Volatile Revenue And Ongoing LossesRevenue concentration in licensing events creates an uneven earnings profile, while limited product sales and persistent losses show that the commercial base is not yet self-sustaining. This increases dependence on future milestones and approvals.
Regulatory Execution UncertaintyReliance on an investigator-initiated study for regulatory submission introduces execution and timing risk. Further delays could defer potential approval, commercialization planning and related milestone or royalty opportunities.
Lexicon Pharmaceuticals News
LXRX FAQ
What was Lexicon Pharmaceuticals’s price range in the past 12 months?
Lexicon Pharmaceuticals lowest stock price was $1.03 and its highest was $2.68 in the past 12 months.
What is Lexicon Pharmaceuticals’s market cap?
Lexicon Pharmaceuticals’s market cap is $1.02B.
When is Lexicon Pharmaceuticals’s upcoming earnings report date?
Lexicon Pharmaceuticals’s upcoming earnings report date is Nov 11, 2026 which is in 78 days.
How were Lexicon Pharmaceuticals’s earnings last quarter?
Lexicon Pharmaceuticals released its earnings results on Aug 06, 2026. The company reported -$0.07 earnings per share for the quarter, missing the consensus estimate of -$0.05 by -$0.02.
Is Lexicon Pharmaceuticals overvalued?
According to Wall Street analysts Lexicon Pharmaceuticals’s price is currently Undervalued.
Does Lexicon Pharmaceuticals pay dividends?
Lexicon Pharmaceuticals does not currently pay dividends.
What is Lexicon Pharmaceuticals’s EPS estimate?
Lexicon Pharmaceuticals’s EPS estimate is -0.06.
How many shares outstanding does Lexicon Pharmaceuticals have?
Lexicon Pharmaceuticals has 444,955,930 shares outstanding.
What happened to Lexicon Pharmaceuticals’s price movement after its last earnings report?
Lexicon Pharmaceuticals reported an EPS of -$0.07 in its last earnings report, missing expectations of -$0.05. Following the earnings report the stock price went down -3.673%.
Which hedge fund is a major shareholder of Lexicon Pharmaceuticals?
Currently, no hedge funds are holding shares in LXRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lexicon Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.00 (162.01% Upside)
$6.00 (162.01% Upside)
Blogger Sentiment
Bullish
LXRX Sentiment 67%
Sector Average 60%
Sector Average 60%
Hedge Fund Trend
Decreased
By 59.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.2%
Last 30 Days ▼ 1.9%
Last 30 Days ▼ 1.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
102.72%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
10.85%
Trailing 12-Months
Company Description
Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the end-to-end process of identifying, advancing, and bringing to market novel therapeutic compounds. Its development pipeline includes orally administered small molecule drug candidates such as Sotagliflozin, which has successfully concluded Phase III clinical studies for treating both heart failure and type 1 diabetes, and LX9211, currently undergoing Phase II clinical development for neuropathic pain. The firm maintains important strategic collaborations and licensing arrangements with pharmaceutical industry leaders, including Bristol-Myers Squibb Company and Genentech, Inc. Established in 1995, Lexicon Pharmaceuticals, Inc. is based in The Woodlands, Texas.
LXRX Company Deck
LXRX Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted meaningful clinical and strategic progress — notably the over-enrollment of SONATA-HCM, approaching NDA resubmission for Zynquista supported by favorable STENO1 exposure and DKA data, international regulatory activity, and milestone-driven partnership progress (LX9851) — and the company strengthened liquidity with cash rising to $190.6M and a new Hercules loan facility. Counterbalancing these positives were a steep year-over-year revenue decline (driven by lack of prior-period licensing revenue), a return to a net loss of $31.8M, increased R&D spending, and some timing uncertainty due to reliance on an investigator-led study for NDA formatting and submission. Overall, the call presented strong operational and pipeline momentum alongside expected near-term financial volatility as the company invests in late-stage programs.View all LXRX earnings summariesLXRX Stock 12 Month Forecast
Average Price Target
$6.00
▲(162.01% Upside)
Technical Analysis
Ownership Overview
61.24% Insiders
7.88% Mutual Funds
0.35% Other Institutional Investors
24.58% Public Companies and
Individual Investors